Pharma Stocks Soar After US Senate Passes Biosecure Act; Wockhardt Leads Gains

• Indian pharma stocks rallied up to 5% after the US Senate passed the 'Biosecure Act'.
• The Act restricts certain Chinese biotech firms from accessing US federal funding.
• India is seen as a key beneficiary, especially Contract Development and Manufacturing Organizations (CDMOs) like Divi's Laboratories.
• Wockhardt surged 5%, leading gains, with Laurus Labs and Divi's Laboratories also seeing significant rises.
• The Biosecure Act, part of the NDAA, aims to curb China's influence in biotech supply chains and prevent espionage.

Why It Matters: US Biosecure Act boosts Indian pharma, with Wockhardt leading gains, as China's biotech funding is restricted.